+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Polycystic Kidney Disease (PKD) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4845162
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 153 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

‘Polycystic Kidney Disease (PKD)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PKDs in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Polycystic Kidney Disease (PKD) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)
Study Period:2017-2028

Polycystic Kidney Disease (PKD) - Disease Understanding and Treatment Algorithm

Polycystic kidney disease (PKD) is part of a heterogeneous group of disorders characterized by renal cysts and numerous systemic and extrarenal manifestations. In patients with PKD, the kidneys contain multiple fluid-filled cysts. People with PKD can also have cysts in the liver (mainly) and problems in other organs, such as the heart and blood vessels in the brain. Although PKD is inherited monogenically, it is phenotypically, genetically, and allelically heterogeneous.

The Polycystic Kidney Disease (PKD) market report gives the thorough understanding of the Polycystic Kidney Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Polycystic Kidney Disease in Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Polycystic Kidney Disease Epidemiology

The Polycystic Kidney Disease (PKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients) scenario of Polycystic Kidney Disease (PKD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

According to this report, the total number of prevalent cases of Polycystic Kidney Disease (PKD) in 10 EM was found to be 1,912,820, in the year 2017.

Polycystic Kidney Disease Drug Chapters

This segment of the Polycystic Kidney Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast focuses on the market revenue generated by the pharmacological treatment which are primarily symptomatic or palliative in nature. Antihypertensive drugs to slow the deterioration of Renal Function, Antibiotics to treat UTI or infected renal cysts and Analgesics to control renal pain. Immunosuppresants from another important class of drugs used only in patients undergoing Renal Transplant. It is to be noted that only a small fraction of the entire diagnosed PKD patient pool can opt for or are eligible for undergoing such surgical interventions. Therefore immunosuppressant drugs constitute a significantly lesser amount of share as compared to other supportive therapies.

Polycystic Kidney Disease Market Outlook

The Polycystic Kidney Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this report, the market of Polycystic Kidney Disease in 10EM was found to be USD 83.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Polycystic Kidney Disease, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Polycystic Kidney Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Polycystic Kidney Disease Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Polycystic Kidney Disease Report Key Strengths
  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Polycystic Kidney Disease Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Polycystic Kidney Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Polycystic Kidney Disease market
  • To understand the future market competition in the Polycystic Kidney Disease market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1. Key Insights

2. PKD Market Overview at a Glance
2.1. Market Share (%) Distribution of PKD in 2017
2.2. Market Share (%) Distribution of PKD in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. Types
3.3. Causes
3.4. Risk Factors
3.5. Signs and symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.8. Biomarkers
3.9. Other Complications associated with PKD

4. Epidemiology and Patient Population - By Region
4.1. Key Findings
4.2. KOL views

5. Ten Emerging Markets (EM) Total Prevalent Population of Polycystic kidney disease (PKD)
5.1. Total Prevalence of PKD in 10 Emerging Markets
5.2. Prevalence of AD-PKD in 10 Emerging Markets

6. Region Wise-Epidemiology of Polycystic kidney disease (PKD)
6.1. Asia and East Europe (China, Taiwan, Saudi Arabia, UAE, Russia, and Turkey)
6.1.1. Assumptions and Rationale:
6.1.1.1. China
6.1.1.2. Total Prevalent Cases of PKD in China
6.1.1.2.1. Prevalence of PKD by Types in China
6.1.1.2.2. Prevalent Cases of PKD by Gender in China
6.1.1.2.3. Diagnosed Prevalence of PKD in China
6.1.1.2.4. Clinical Manifestations in Patients of ADPKD in China
6.1.1.2.5. Transplant Eligible PKD Patients in China
6.1.1.3. Taiwan
6.1.1.3.1. Total Prevalent Cases of PKD in Taiwan
6.1.1.3.2. Prevalence of PKD by Types in Taiwan
6.1.1.3.3. Prevalent Cases of PKD by Gender in Taiwan
6.1.1.3.4. Diagnosed Prevalence of PKD in Taiwan
6.1.1.3.5. Clinical Manifestations in Patients of ADPKD in Taiwan
6.1.1.3.6. Transplant Eligible PKD Patients in Taiwan
6.1.1.4. Saudi Arabia
6.1.1.4.1. Total Prevalent Cases of PKD in Saudi Arabia
6.1.1.4.2. Prevalence of PKD by Types in Saudi Arabia
6.1.1.4.3. Prevalent Cases of PKD by Gender in Saudi Arabia
6.1.1.4.4. Diagnosed Prevalence of PKD in Saudi Arabia
6.1.1.4.5. Clinical Manifestations in Patients of ADPKD in Saudi Arabia
6.1.1.4.6. Transplant Eligible PKD Patients in Saudi Arabia
6.1.1.5. UAE
6.1.1.5.1. Total Prevalent Cases of PKD in UAE
6.1.1.5.2. Prevalence of PKD by Types in UAE
6.1.1.5.3. Prevalent Cases of PKD by Gender in UAE
6.1.1.5.4. Diagnosed Prevalence of PKD in UAE
6.1.1.5.5. Clinical Manifestations in Patients of ADPKD in UAE
6.1.1.5.6. Transplant Eligible PKD Patients in UAE
6.1.1.6. Turkey
6.1.1.6.1. Total Prevalent Cases of PKD in Turkey
6.1.1.6.2. Prevalence of PKD by Types in Turkey
6.1.1.6.3. Prevalent Cases of PKD by Gender in Turkey
6.1.1.6.4. Diagnosed Prevalence of PKD in Turkey
6.1.1.6.5. Clinical Manifestations in Patients of ADPKD in Turkey
6.1.1.6.6. Transplant Eligible PKD Patients in Turkey
6.1.1.7. Russia
6.1.1.7.1. Total Prevalent Cases of PKD in Russia
6.1.1.7.2. Prevalence of PKD by Types in Russia
6.1.1.7.3. Prevalent Cases of PKD by Gender in Russia
6.1.1.7.4. Diagnosed Prevalence of PKD in Russia
6.1.1.7.5. Clinical Manifestations in Patients of ADPKD in Russia
6.1.1.7.6. Transplant Eligible PKD Patients in Russia
6.2. LATAM (Colombia, Brazil, Argentina, and Mexico)
6.2.1. Assumptions and Rationale:
6.2.1.1. Colombia
6.2.1.1.1. Total Prevalent Cases of PKD in Colombia
6.2.1.1.2. Prevalence of PKD by Types in Colombia
6.2.1.1.3. Prevalent Cases of PKD by Gender in Colombia
6.2.1.1.4. Diagnosed Prevalence of PKD in Colombia
6.2.1.1.5. Clinical Manifestations in Patients of ADPKD in Colombia
6.2.1.1.6. Transplant Eligible PKD Patients in Colombia
6.2.1.2. Brazil
6.2.1.2.1. Total Prevalent Cases of PKD in Brazil
6.2.1.2.2. Prevalence of PKD by Types in Brazil
6.2.1.2.3. Prevalent Cases of PKD by Gender in Brazil
6.2.1.2.4. Diagnosed Prevalence of PKD in Brazil
6.2.1.2.5. Clinical Manifestations in Patients of ADPKD in Brazil
6.2.1.2.6. Transplant Eligible PKD Patients in Brazil
6.2.1.3. Argentina
6.2.1.3.1. Total Prevalent Cases of PKD in Argentina
6.2.1.3.2. Prevalence of PKD by Types in Argentina
6.2.1.3.3. Prevalent Cases of PKD by Gender in Argentina
6.2.1.3.4. Diagnosed Prevalence of PKD in Argentina
6.2.1.3.5. Clinical Manifestations in Patients of ADPKD in Argentina
6.2.1.3.6. Transplant Eligible PKD Patients in Argentina
6.2.1.4. Mexico
6.2.1.4.1. Total Prevalent Cases of PKD in Mexico
6.2.1.4.2. Prevalence of PKD by Types in Mexico
6.2.1.4.3. Prevalent Cases of PKD by Gender in Mexico
6.2.1.4.4. Diagnosed Prevalence of PKD in Mexico
6.2.1.4.5. Clinical Manifestations in Patients of ADPKD in Mexico
6.2.1.4.6. Transplant Eligible PKD Patients in Mexico

7. Treatment and Management of Polycystic Kidney Disease

8. Unmet Needs

9. Emerging Therapies
9.1. Tolvaptan: Otsuka Pharmaceutical Co., Ltd.
9.1.1. Product Description
9.1.2. Product Development Activities
9.1.3. Safety and Efficacy
9.1.4. Product Profile
9.2. Bardoxolone methyl: Reata Pharmaceuticals, Inc.
9.2.1. Product Description
9.2.2. Product Development Activities
9.2.3. Clinical development
9.2.3.1. Clinical Trials Information
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Venglustat: Sanofi Genzyme
9.3.1. Product Description
9.3.2. Product Development Activities
9.3.3. Clinical development
9.3.3.1. Clinical Trials Information
9.3.4. Safety and Efficacy
9.3.5. Product Profile

10. Polycystic kidney disease (PKD): 10 EM Analysis
10.1. Key Findings
10.2. KOL Views
10.3. Market Size of Polycystic kidney disease (PKD) in 10 EM
10.3.1. Market Size of PKD by Therapies

11. Market Outlook by Country
11.1. Emerging Markets: Market Outlook
11.2. China
11.2.1. Total Market Size of Polycystic kidney disease
11.2.2. Market Size of Polycystic kidney disease by Therapies
11.3. Taiwan
11.3.1. Total Market Size of Polycystic kidney disease
11.3.2. Market Size of Polycystic kidney disease by Therapies
11.4. Saudi Arabia
11.4.1. Total Market Size of Polycystic kidney disease
11.4.2. Market Size of Polycystic kidney disease by Therapies
11.5. UAE
11.5.1. Total Market Size of Polycystic kidney disease
11.5.2. Market Size of Polycystic kidney disease by Therapies
11.6. Turkey
11.6.1. Total Market Size of Polycystic kidney disease
11.6.2. Market Size of Polycystic kidney disease by Therapies
11.7. Russia
11.7.1. Total Market Size of Polycystic kidney disease
11.7.2. Market Size of Polycystic kidney disease by Therapies
11.8. Colombia
11.8.1. Total Market Size of Polycystic kidney disease
11.8.2. Market Size of Polycystic kidney disease by Therapies
11.9. Brazil
11.9.1. Total Market Size of Polycystic kidney disease
11.9.2. Market Size of Polycystic kidney disease by Therapies
11.10. Argentina
11.10.1. Total Market Size of Polycystic kidney disease
11.10.2. Market Size of Polycystic kidney disease by Therapies
11.11. Mexico
11.11.1. Total Market Size of Polycystic kidney disease
11.11.2. Market Size of Polycystic kidney disease by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix
14.1. Report Methodology

15. Capabilities

16. Disclaimer

17. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi (Genzyme)
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
Adroll
adroll